South Korea · Delayed Price · Currency is KRW SK Biopharmaceuticals Statistics
Total Valuation
KRX:326030 has a market cap or net worth of KRW 7.75 trillion. The enterprise value is 7.51 trillion.
| Market Cap | 7.75T |
| Enterprise Value | 7.51T |
Important Dates
The next estimated earnings date is Monday, May 11, 2026.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:326030 has 78.31 million shares outstanding.
| Current Share Class | 78.31M |
| Shares Outstanding | 78.31M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 13.56% |
| Float | 38.97M |
Valuation Ratios
The trailing PE ratio is 29.04 and the forward PE ratio is 29.32. KRX:326030's PEG ratio is 3.22.
| PE Ratio | 29.04 |
| Forward PE | 29.32 |
| PS Ratio | 10.97 |
| PB Ratio | 9.38 |
| P/TBV Ratio | 9.62 |
| P/FCF Ratio | 45.76 |
| P/OCF Ratio | 43.97 |
| PEG Ratio | 3.22 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 40.23, with an EV/FCF ratio of 44.30.
| EV / Earnings | 28.12 |
| EV / Sales | 10.62 |
| EV / EBITDA | 40.23 |
| EV / EBIT | 44.25 |
| EV / FCF | 44.30 |
Financial Position
The company has a current ratio of 2.31, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.31 |
| Quick Ratio | 1.83 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.22 |
| Debt / FCF | 0.29 |
| Interest Coverage | 26.52 |
Financial Efficiency
Return on equity (ROE) is 36.17% and return on invested capital (ROIC) is 38.91%.
| Return on Equity (ROE) | 36.17% |
| Return on Assets (ROA) | 11.41% |
| Return on Invested Capital (ROIC) | 38.91% |
| Return on Capital Employed (ROCE) | 22.58% |
| Weighted Average Cost of Capital (WACC) | 8.44% |
| Revenue Per Employee | 2.87B |
| Profits Per Employee | 1.09B |
| Employee Count | 246 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 0.40 |
Taxes
| Income Tax | -102.37B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.30% in the last 52 weeks. The beta is 0.76, so KRX:326030's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -0.30% |
| 50-Day Moving Average | 108,112.00 |
| 200-Day Moving Average | 109,690.50 |
| Relative Strength Index (RSI) | 46.99 |
| Average Volume (20 Days) | 766,879 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:326030 had revenue of KRW 706.74 billion and earned 266.95 billion in profits. Earnings per share was 3,408.75.
| Revenue | 706.74B |
| Gross Profit | 663.84B |
| Operating Income | 203.94B |
| Pretax Income | 150.88B |
| Net Income | 266.95B |
| EBITDA | 220.89B |
| EBIT | 203.94B |
| Earnings Per Share (EPS) | 3,408.75 |
Balance Sheet
The company has 309.48 billion in cash and 48.92 billion in debt, with a net cash position of 260.56 billion or 3,327.18 per share.
| Cash & Cash Equivalents | 309.48B |
| Total Debt | 48.92B |
| Net Cash | 260.56B |
| Net Cash Per Share | 3,327.18 |
| Equity (Book Value) | 826.27B |
| Book Value Per Share | 10,381.84 |
| Working Capital | 388.03B |
Cash Flow
In the last 12 months, operating cash flow was 176.33 billion and capital expenditures -6.89 billion, giving a free cash flow of 169.44 billion.
| Operating Cash Flow | 176.33B |
| Capital Expenditures | -6.89B |
| Depreciation & Amortization | 16.95B |
| Net Borrowing | -156.68B |
| Free Cash Flow | 169.44B |
| FCF Per Share | 2,163.64 |
Margins
Gross margin is 93.93%, with operating and profit margins of 28.86% and 37.77%.
| Gross Margin | 93.93% |
| Operating Margin | 28.86% |
| Pretax Margin | 21.35% |
| Profit Margin | 37.77% |
| EBITDA Margin | 31.25% |
| EBIT Margin | 28.86% |
| FCF Margin | 23.98% |
Dividends & Yields
KRX:326030 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 3.44% |
| FCF Yield | 2.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KRX:326030 has an Altman Z-Score of 14.75 and a Piotroski F-Score of 6.
| Altman Z-Score | 14.75 |
| Piotroski F-Score | 6 |